Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis

Cancer Science

Volumn 105, Issue 7, 2014, Pages 818-824

  Meng, Xiangjiao ^a,b   Wang, Renben ^b   Huang, Zhaoqin ^c   Zhang, Jianbo ^b   Feng, Rui ^b   Xu, Xiaoqing ^b   Zhu, Kunli ^b   Dou, Xue ^b   Chen, Dong ^b   Yu, Jinming ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

HER 2; Neoadjuvant chemoradiotherapy; Rectal cancer; Survival; Tumor response

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT RESPONSE; TUMOR REGRESSION;

HER-2; NEOADJUVANT CHEMORADIOTHERAPY; RECTAL CANCER; SURVIVAL; TUMOR RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904320190     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12421     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM et al. Forman D: global cancer statistics. CA Cancer J Clin 2011; 61: 69-70.
2. van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-Year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-82.
3. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
4. Roh MS, Colangelo LH, O'Connell MJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-30.
5. Rödel C, Liersch T, Becker H et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO(ARO/AIO-04 randomised phase3 trial. Lancet Oncol 2012; 13: 679-87.
6. Eich HT, Stepien A, Zimmermann C et al. Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther Onkol 2001; 187: 225-30.
7. Schechter AL, Stern DF, Vaidyanathan L. The neu oncogene: an erb-B-related gene encoding a 185 000-M(r) tumour antigen. Nature 1984; 312: 513-6.
8. Casalini P, Iorio MV, Galmozzi E et al. Role of HER receptors family in development and differentiation. J Cell Physiol 2004; 200: 343-50.
9. Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-9.
10. Eriksen JG, Steiniche T, Overgaard J et al. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 Study. Radiother Oncol 2005; 74: 93-100.
11. Giralt J, Eraso A, Armengol M et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1460-5.
12. Kim JS, Kim JM, Li S et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 195-200.
13. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10: 139-52.
14. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12: S3-8.
15. Tangjitgamol S, Tanvanich S, Srijaipracharoen S et al. Expression of estrogen receptor, progesterone receptor, and Her-2/neu in primary and extra-corporeal endometrial cancer. Histol Histopathol 2013; 28: 787-94.
16. Hirashima N, Takahashi W, Yoshii S et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001; 14: 556-62.
17. Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-50.
18. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
19. Yoon HH, Shi Q, Sukov WR et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012; 15: 546-54.
20. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010; 116: 5336-9.
21. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
22. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-9.
23. Park DI, Kang MS, Oh SJ et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007; 22: 491-7.
24. Drebber U, Madeja M, Odenthal M et al. β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. Int J Colorectal Dis 2011; 26: 1127-34.
25. Lim SW, Kim HR, Kim HY et al. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol (Dordr) 2013; 36: 311-21.
26. Conradi LC, Styczen H, Sprenger T et al. Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. Am J Surg Pathol 2013; 37: 522-31.
27. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
28. Martin V, Landi L, Molinari F et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108: 668-75.
29. Rödel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96.
30. Rosenberg R, Nekarda H, Zimmermann F et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol 2008; 97: 8-13.
31. Harada S, Mick R, Roses RE et al. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol 2011; 104: 458-65.
32. Osako T, Miyahara M, Uchino S et al. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-55.
33. Gérard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of thephase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-44.
34. Gérard JP, Azria D, Gourgou-Bourgade S et al. Clinical results at 3 years of the accord 12 randomized trial in rectal cancer [abstract]. ASCO Meeting Abstracts 2012; 30: 389.
35. Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer:pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-80.